Altimmune Inc (ALT) Stock Price, Quote & News

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology

Sector: Healthcare

Phone: 240 654 1450

Website: altimmune.com

Address:

910 Clopper Road, Suite 201S, Gaithersburg, United States

AdeptPaper Aug. 1 at 12:29 PM

$ALT https://www.reuters.com/business/healthcare-pharmaceuticals/us-plans-medicare-medicaid-coverage-weight-loss-drugs-washington-post-reports-2025-08-01/

1 · Reply

ZACHSPIZZA Aug. 1 at 12:20 PM

$ALT buys at $3.50,$3.25,$3 GL that better be as low as she goes if markets take a breather.

0 · Reply

GreenEnergy2022 Aug. 1 at 12:19 PM

$ALT "No more ozempic face, lose fat - and keep your muscle." This is a drug $NVO needs. But $PFE is also on shopping. Novo going green. Did we see the bottom in Obesity stocks?

0 · Reply

Damnthisappilosthistory Aug. 1 at 12:11 PM

$ALT I really hope we are competitive and differentiated enough tbh.. WL seems lower but we have great muscle mass preservation. Is it enough to generate M&A interest from BP? Comment please.

1 · Reply

Paul4321 Aug. 1 at 12:08 PM

$ALT I’m readjusting expected timeline for end of P2 MASH FDA package submission to August/early Sept taking into consideration 24weeks data was released in late June. With fast track ergo rolling review ALT can throw in fibrosis later if it hits endpoint after 48 Weeks (48 Weeks ends 2nd/3rd August). I’m also changing my opinion to 2nd quarter earnings is the more logical event over annual shareholder meeting to hear about any update on MASH trial/FDA meeting.

1 · Reply

Jacked_Nicholson Aug. 1 at 12:08 PM

$ALT IMO the top 3 potential suitors are: - Pfizer (actively looking for one or more acquisitions, talks about tolerability, lean mass preservation) - Novo (In a turmoil) - Gilead (liver focused, Altimmune job offer copy pasted from Gilead)

2 · Reply

BossHogg1919 Aug. 1 at 11:19 AM

$ALT Bloody Friday.

1 · Reply

fullregalia Aug. 1 at 11:15 AM

$ALT nothing new, can't hurt https://finimize.com/content/alt-asset-snapshot

0 · Reply

Damnthisappilosthistory Aug. 1 at 11:12 AM

$ALT well we can only hope that there’s some interest from BPs. Pfizer CEO mentioned he’d like to acquire a cardiometabolic drug, liked weight loss. Lets pray mgmt realises they can’t GIA

0 · Reply

CowPie_ Aug. 1 at 10:51 AM

$ALT

0 · Reply

ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm

Jul 9, 2025, 7:30 AM EDT - 23 days ago

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)

Jun 27, 2025, 2:39 PM EDT - 4 weeks ago

Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

Jun 26, 2025, 4:30 PM EDT - 5 weeks ago

Altimmune: Deciphering The MASH Crash (Rating Upgrade)

Jun 26, 2025, 2:59 PM EDT - 5 weeks ago

Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide

Jun 26, 2025, 8:16 AM EDT - 5 weeks ago

Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

BTBT KTOS

Jun 26, 2025, 7:43 AM EDT - 5 weeks ago

Altimmune's weight-loss drug meets main goal in fatty liver disease trial

Jun 26, 2025, 7:00 AM EDT - 5 weeks ago

Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

Jun 25, 2025, 7:12 PM EDT - 5 weeks ago

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

Jun 13, 2025, 7:30 AM EDT - 7 weeks ago

Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions

Jun 2, 2025, 10:51 AM EDT - 2 months ago

Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential

VKTX

May 29, 2025, 10:25 AM EDT - 2 months ago

Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity

May 19, 2025, 7:30 AM EDT - 2 months ago

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

May 14, 2025, 7:30 AM EDT - 2 months ago

Altimmune to Participate at Two Upcoming Investor Conferences

May 13, 2025, 2:57 PM EDT - 2 months ago

Altimmune, Inc. (ALT) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:00 AM EDT - 2 months ago

Altimmune Announces First Quarter 2025 Financial Results and Business Update

May 13, 2025, 7:00 AM EDT - 2 months ago

Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

HTGC

May 8, 2025, 7:30 AM EDT - 3 months ago

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

May 6, 2025, 7:30 AM EDT - 3 months ago

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

May 1, 2025, 7:30 AM EDT - 3 months ago

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025

Apr 30, 2025, 7:30 AM EDT - 3 months ago

Altimmune to Participate in the Citizens Life Sciences Conference

Mar 17, 2025, 3:21 PM EDT - 4 months ago

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine

Mar 13, 2025, 5:26 PM EDT - 5 months ago

Altimmune to test obesity drug for alcohol use disorder and related health conditions

Mar 6, 2025, 7:30 AM EST - 5 months ago

Altimmune to Host Virtual R&D Day on March 13, 2025

Mar 3, 2025, 7:30 AM EST - 5 months ago

Altimmune to Participate in the Leerink Global Healthcare Conference

Feb 28, 2025, 2:15 PM EST - 5 months ago

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Feb 27, 2025, 2:24 PM EST - 5 months ago

Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:00 AM EST - 5 months ago

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Feb 25, 2025, 7:30 AM EST - 5 months ago

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

Feb 20, 2025, 7:30 AM EST - 5 months ago

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

Feb 18, 2025, 5:26 AM EST - 5 months ago

Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH

Feb 14, 2025, 6:32 PM EST - 5 months ago

Final Trade: WST, BTC, GLD, ALT

GLD BTC WST

Jan 29, 2025, 7:30 AM EST - 6 months ago

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

Dec 30, 2024, 11:42 AM EST - 7 months ago

Altimmune Could Find A Partner For Its Phase 3 Exercise

Dec 19, 2024, 7:30 AM EST - 8 months ago

Altimmune Added to Nasdaq Biotechnology Index

Dec 16, 2024, 3:14 AM EST - 8 months ago

Altimmune 2025: Redefining Obesity And MASH Treatment

Dec 3, 2024, 6:04 PM EST - 8 months ago

Altimmune CEO on what's next for its experimental obesity drug

Nov 19, 2024, 6:29 PM EST - 9 months ago

Final Trade: C, NVDA, XLF, ALT

NVDA XLF C

Nov 15, 2024, 11:00 AM EST - 9 months ago

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

Nov 13, 2024, 3:43 PM EST - 9 months ago

Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge

Nov 13, 2024, 12:38 PM EST - 9 months ago

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Nov 12, 2024, 10:00 AM EST - 9 months ago

Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 7:30 AM EST - 9 months ago

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 11, 2024, 7:30 AM EST - 9 months ago

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

Nov 7, 2024, 7:30 AM EST - 9 months ago

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity

Nov 4, 2024, 7:30 AM EST - 9 months ago

Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

AdeptPaper Aug. 1 at 12:29 PM

$ALT https://www.reuters.com/business/healthcare-pharmaceuticals/us-plans-medicare-medicaid-coverage-weight-loss-drugs-washington-post-reports-2025-08-01/

1 · Reply

ZACHSPIZZA Aug. 1 at 12:20 PM

$ALT buys at $3.50,$3.25,$3 GL that better be as low as she goes if markets take a breather.

0 · Reply

GreenEnergy2022 Aug. 1 at 12:19 PM

$ALT "No more ozempic face, lose fat - and keep your muscle." This is a drug $NVO needs. But $PFE is also on shopping. Novo going green. Did we see the bottom in Obesity stocks?

0 · Reply

Damnthisappilosthistory Aug. 1 at 12:11 PM

$ALT I really hope we are competitive and differentiated enough tbh.. WL seems lower but we have great muscle mass preservation. Is it enough to generate M&A interest from BP? Comment please.

1 · Reply

Paul4321 Aug. 1 at 12:08 PM

1 · Reply

Jacked_Nicholson Aug. 1 at 12:08 PM

2 · Reply

BossHogg1919 Aug. 1 at 11:19 AM

$ALT Bloody Friday.

1 · Reply

fullregalia Aug. 1 at 11:15 AM

$ALT nothing new, can't hurt https://finimize.com/content/alt-asset-snapshot

0 · Reply

Damnthisappilosthistory Aug. 1 at 11:12 AM

$ALT well we can only hope that there’s some interest from BPs. Pfizer CEO mentioned he’d like to acquire a cardiometabolic drug, liked weight loss. Lets pray mgmt realises they can’t GIA

0 · Reply

CowPie_ Aug. 1 at 10:51 AM

$ALT

0 · Reply

Mssch Aug. 1 at 10:17 AM

$ALT Premarket frozen

0 · Reply

Mssch Aug. 1 at 10:04 AM

$ALT Is it halted? No movement in a falling market

4 · Reply

Definvest Aug. 1 at 7:02 AM

$ALT

0 · Reply

EggHeadeds Aug. 1 at 6:25 AM

$ALT My late night thoughts... “The storm only feels eternal when you forget the sky exists beyond the clouds.” In every investor’s journey, there comes a moment when doubt feels louder than reason, and fear knocks louder than hope. But just as a tree doesn’t stop growing because of one harsh winter, your belief in what is possible shouldn’t wither from a single bad season. Altimmune’s path is not defined by a day, a chart, or a percentage. It is defined by science, by time, and by the quiet persistence of those who build while others panic. The real story is still being written — not in red candles, but in data, determination, and direction. If you believed when it was easy, believe now that it’s hard. For it’s in the silence after the fall that the phoenix begins to rise. Keep your spirit calm. The journey is far from over. 🌙

3 · Reply

Chalutz Aug. 1 at 6:11 AM

$ALT Mgmt played into MMs and Shorts hands. Every move ALT made has been a disaster so like Jets owner their’s real incompetence and stupidity involved. But same story in too many biotechs is sign of a fundamental, systematic, mkt problem. Quasi regulatory bodies are stacked in favor of MMs and shorts. I literally just read biography of NASDAQ‘s Board. Not one with a FN modicum of experience in biotech, building a CO, raising money an entrepreneur etc. A bunch of big Co FN LAPDOGS , MMs and shorts are manipulate like biotechs, small stocks etc. PRE- REVENUE Cos shouldn’t be subject to same NASDAQ RULES as APPLE, MICROSOFT, TESLA, ETC. ITS SO FN ABSURD!!!! They need separate division , exchange and rules with more protection against criminal market manipulation , FN $1 delisting rule etc . We gotta do something

1 · Reply

namv Aug. 1 at 4:23 AM

$ALT come on Garg now’s not the time to be shy

0 · Reply

Chalutz Aug. 1 at 3:14 AM

$ALT @Diapers_Tequila I ’m going to send a copy of my email I just sent about the inappropriateness of having ALT IN THE NASDAQ WEEKLY OPTIONS PROGRAM to ALT and tell them to pass along to GARG ET AL. I sent my email regarding weekly emails and the ridiculous $0.05 , $5 minimum tick size versus $0.01, $1 tick size for a stock with this type of OPTION OPEN INTEREST and VOLUME to following email addresses [email protected] [email protected] [email protected] Does anyone have any additional Altimmune emails besides [email protected] GLTA!!!!

1 · Reply

romanaround Aug. 1 at 3:13 AM

$ALT hey I see you I got a life line for ya $NVO

0 · Reply

ItIsGoTime Aug. 1 at 3:11 AM

$ALT

0 · Reply

WallStreetBuyDip Aug. 1 at 3:01 AM

$ALT great ticker for trading

0 · Reply

EggHeadeds Aug. 1 at 2:47 AM

$ALT In the cramped bylanes of Mumbai’s slums, you’ll often find rabid dogs barking at anything that moves or doesn’t. The smart ones just keep walking. Try to reason or confront, and you might end up foaming too. Best to preserve your sanity and let the madness bark itself out.

0 · Reply

Jcordless Aug. 1 at 2:38 AM

$ALT your a weirdo bud, do you think anyone actually reads all your spam?

1 · Reply

Market Cap	296.04M
Revenue (ttm)	20,000.00
Net Income (ttm)	-95.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-475,300.00%
Debt to Equity Ratio	0.00

Volume	2,734,500
Avg Vol	6,496,974
Day's Range	N/A - N/A
Shares Out	81.11M
Stochastic %K	14%
Beta	0.47
Analysts	Strong Sell
Price Target	$18.89